These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 10037369

  • 1. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C, Pandrangi L, Agarwal A.
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [Abstract] [Full Text] [Related]

  • 2. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A.
    Anticancer Res; 1999 Jan; 19(4A):2621-3. PubMed ID: 10470205
    [Abstract] [Full Text] [Related]

  • 3. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A.
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [Abstract] [Full Text] [Related]

  • 4. Screening and monitoring for bladder cancer: refining the use of NMP22.
    Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, Zippe CD.
    J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827
    [Abstract] [Full Text] [Related]

  • 5. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS, Bagiella E, Sawczuk AT, Yun EJ.
    Cancer Detect Prev; 2000 Jul; 24(4):364-8. PubMed ID: 11059567
    [Abstract] [Full Text] [Related]

  • 6. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [Abstract] [Full Text] [Related]

  • 7. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A, Kumar R, Gupta NP.
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y, Goktas S, Kilic S, Yaman H, Onguru O, Peker AF.
    Ann Clin Lab Sci; 2006 Mar; 36(1):31-8. PubMed ID: 16501234
    [Abstract] [Full Text] [Related]

  • 9. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
    Sánchez-Carbayo M, Urrutia M, Silva JM, Romaní R, De Buitrago JM, Navajo JA.
    J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K.
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [Abstract] [Full Text] [Related]

  • 11. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C.
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [Abstract] [Full Text] [Related]

  • 12. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF.
    Cancer; 2006 Apr 15; 106(8):1701-7. PubMed ID: 16541433
    [Abstract] [Full Text] [Related]

  • 13. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R, Huber P, Blöchlinger A, Stoffel F, Dalquen P, Gasser TC, Lehmann K.
    J Urol; 2000 Dec 15; 164(6):1926-8. PubMed ID: 11061883
    [Abstract] [Full Text] [Related]

  • 14. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM, Kiemeney LA, Witjes JA.
    Eur Urol; 2005 Dec 15; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H, Miyanaga N, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K.
    Gan To Kagaku Ryoho; 1997 May 15; 24(7):829-36. PubMed ID: 9170521
    [Abstract] [Full Text] [Related]

  • 16. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, Al-Maghrebi M, Al-Mulla F.
    Cytopathology; 2008 Dec 15; 19(6):369-74. PubMed ID: 18631356
    [Abstract] [Full Text] [Related]

  • 17. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
    Parekattil SJ, Fisher HA, Kogan BA.
    J Urol; 2003 Mar 15; 169(3):917-20. PubMed ID: 12576812
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, Talbot-Wright R.
    Anticancer Res; 2000 Mar 15; 20(2B):1169-72. PubMed ID: 10810416
    [Abstract] [Full Text] [Related]

  • 19. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
    Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, Lotan Y, Marberger MJ, Shariat SF.
    BJU Int; 2008 Mar 15; 101(5):561-5. PubMed ID: 18257856
    [Abstract] [Full Text] [Related]

  • 20. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
    Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI.
    BJU Int; 2009 May 15; 103(10):1368-74. PubMed ID: 19338566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.